Neurological biomarkers are biological indicators present in the cerebrospinal fluid that can be measured to study the health of the brain. Neurological biomarkers can be of various types such as imaging biomarkers, metabolomics biomarkers, proteomic biomarkers, and genomics biomarkers. Neurological biomarkers help in the early diagnosis of neurological disorders such as epilepsy, brain tumor, Alzheimer’s, Parkinson’s disease, multiple sclerosis, and others. These biomarkers also assist in monitoring the progress of a neurological disease and studying biological response towards a treatment. Neurological biomarkers captures different characteristics of a disease such as pathogenicity and heterogeneity, which helps in the development of personalized treatment therapy. Rapid research and technological advances in the field of neurology has led to introduction of novel biomarkers that are accurate, reliable and sensitive. According to an article published by the Frontiers in Neurology Journal in January 2019, a computational analysis of gene expression data was carried out in Alzheimer’s disease patients to predict blood-based biomarkers, where the experimental validation was conducted using Enzyme Linked Immuno-sorbent Assay (ELISA) and Western blot analyses. This study led to the discovery of novel neurological biomarker- VLDLR (Very Low Density Lipoprotein Receptor) as a biomarker for Alzheimer's disease.
Market players and research organizations are conducting clinical trial studies for finding out novel neurological biomarkers, which could contribute to the growth of the market over the forecast period. For instance, a clinical study based on neurological biomarkers was initiated by IRCCS Neuromed Mediterranean Neurological Institute, Italy in March 2019, which is expected to be completed by January 2023. This study investigates the use of circulating, cell-free mitochondrial DNA (ccf-mtDNA) as a neurological biomarker for the early detection and prognosis of multiple sclerosis. Such clinical studies is expected to create opportunities for neurological biomarkers market over the forecast period.
Market players are focusing on the launch of products, which is expected to strengthen their position in the global neurological biomarkers market. For instance, in 2018, Biosensis, an Australian manufacturer of life science reagents, launched new BDNF ELISA Kit for accurate measurement of two important blood biomarkers BDNF and pro-BDNF in under four hours. Brain-derived neurotrophic factor (BDNF) biomarker is an important indicator for various neurological and psychiatric disorders such as clinical depression.
Market players are involved in expanding their presence globally, by entering into partnership with other companies in order to enhance distribution, this is expected to drive the growth of the neurological biomarkers market. For instance, in January 2017, Banyan Biomarkers, an American diagnostic tool company, entered into partnership with BioMerieux, a French biotechnology company, to validate and commercialize blood-based neurological biomarkers for in vitro diagnostics for traumatic brain injury (TBI).
Market Dynamics
Market players and research organizations are conducting clinical trial studies for finding out novel neurological biomarkers, which could contribute to the growth of the market over the forecast period. For instance, a clinical study based on neurological biomarkers was initiated by IRCCS Neuromed Mediterranean Neurological Institute, Italy in March 2019, which is expected to be completed by January 2023. This study investigates the use of circulating, cell-free mitochondrial DNA (ccf-mtDNA) as a neurological biomarker for the early detection and prognosis of multiple sclerosis. Such clinical studies is expected to create opportunities for neurological biomarkers market over the forecast period.
Market players are focusing on the launch of products, which is expected to strengthen their position in the global neurological biomarkers market. For instance, in 2018, Biosensis, an Australian manufacturer of life science reagents, launched new BDNF ELISA Kit for accurate measurement of two important blood biomarkers BDNF and pro-BDNF in under four hours. Brain-derived neurotrophic factor (BDNF) biomarker is an important indicator for various neurological and psychiatric disorders such as clinical depression.
Market players are involved in expanding their presence globally, by entering into partnership with other companies in order to enhance distribution, this is expected to drive the growth of the neurological biomarkers market. For instance, in January 2017, Banyan Biomarkers, an American diagnostic tool company, entered into partnership with BioMerieux, a French biotechnology company, to validate and commercialize blood-based neurological biomarkers for in vitro diagnostics for traumatic brain injury (TBI).
Key features of the study:
- This report provides an in-depth analysis of global neurological biomarkers market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global neurological biomarkers market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Abbott Laboratories, QIAGEN N.V., Myriad RBM, Thermo Fisher Scientific Inc., Athena Diagnostics, Bio-Rad Laboratories, Inc., AbaStar MDx, Inc., Acumen Pharmaceuticals, Banyan Biomarkers, Inc., Alseres Pharmaceuticals, Inc., Proteome Sciences, Immunarray Pvt. Ltd., Quanterix Corporation, Diagenic ASA, and Psynova Neurotech
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global neurological biomarkers market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global neurological biomarkers market
Detailed Segmentation:
Global Neurological Biomarkers Market, By Biomarker Type:
- Imaging biomarkers
- Metabolomics Biomarkers
- Proteomic Biomarkers
- Genomics Biomarkers
Global Neurological Biomarkers Market, By Application:
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Autism Spectrum Disorders
- Others
Global Neurological Biomarkers Market, By End User:
- Hospital Laboratories
- Clinical Diagnostic Centers
- Research Organizations
- Others
Global Neurological Biomarkers Market, By Region:
- North America
By Country:
- U.S.
- Canada
- Latin America
By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Abbott Laboratories*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- QIAGEN N.V.
- Myriad RBM
- Thermo Fisher Scientific Inc.
- Athena Diagnostics
- Bio-Rad Laboratories, Inc.
- AbaStar MDx, Inc.
- Acumen Pharmaceuticals
- Banyan Biomarkers, Inc.
- Alseres Pharmaceuticals, Inc.
- Proteome Sciences
- Immunarray Pvt. Ltd.
- Quanterix Corporation
- Diagenic ASA
- Psynova Neurotech
Frequently Asked Questions about the Neurological Biomarkers Market
What is the estimated value of the Neurological Biomarkers Market?
What is the growth rate of the Neurological Biomarkers Market?
What is the forecasted size of the Neurological Biomarkers Market?
Who are the key companies in the Neurological Biomarkers Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 174 |
| Published | August 2021 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD
| USD 8979.6 Million |
| Forecasted Market Value ( USD
| USD 23453.2 Million |
| Compound Annual Growth Rate | 14.7% |
| Regions Covered | Global |
Table of Contents
1. Research Objectives and Assumptions
2. Market Overview
3. Market Dynamics, Regulations, and Trends Analysis
4. COVID - 19 Impact Analysis
5. Global Neurological Biomarkers Market, By Biomarker Type, 2017-2028 (US$ Million)
6. Global Neurological Biomarkers Market, By Application, 2017 - 2028 (US$ Million)
7. Global Neurological Biomarkers Market, By End User, 2017 - 2028 (US$ Million)
8. Global Neurological Biomarkers Market, By Region, 2017 - 2028 (US$ Million)
9. Competitive Landscape
10. Section
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- QIAGEN N.V.
- Myriad RBM
- Thermo Fisher Scientific Inc.
- Athena Diagnostics
- Bio-Rad Laboratories, Inc.
- AbaStar MDx, Inc.
- Acumen Pharmaceuticals
- Banyan Biomarkers, Inc.
- Alseres Pharmaceuticals, Inc.
- Proteome Sciences
- Immunarray Pvt. Ltd.
- Quanterix Corporation
- Diagenic ASA
- Psynova Neurotech
